Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
ADCendo has raised $75.0M in total funding. The most recent round was Series C. The last funding was announced in April 2026.
ADCendo's investors include TPG, RA Capital Management, Bpifrance, Novo Holdings, TCG Crossover.
ADCendo is headquartered in Copenhagen, Denmark.
Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
ADCendo is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ADCendo — Funding & Investors." VCBacked, April 14, 2026, https://www.vcbacked.co/company/adcendo. Accessed July 19, 2026.
VCBacked. (2026). ADCendo — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/adcendo
{{cite web |title=ADCendo — Funding & Investors |url=https://www.vcbacked.co/company/adcendo |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated